{"id":36835,"date":"2026-07-15T19:41:00","date_gmt":"2026-07-15T17:41:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=a5d82659bfffc778dbddd21f0ced0938"},"modified":"2026-07-15T19:41:00","modified_gmt":"2026-07-15T17:41:00","slug":"gempharmatech-and-humlab-global-sign-strategic-agreement-to-deliver-humanized-mouse-models-for-improved-clinical-translation","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=36835","title":{"rendered":"GemPharmatech and Humlab Global Sign Strategic Agreement to Deliver Humanized Mouse Models for Improved Clinical Translation"},"content":{"rendered":"

\nGlobal distribution deal brings Humlab's humanized models spanning aging, autoimmune and metabolic disease, oncology, and infectious disease to GemPharmatech's already robust strain library and international research network.<\/i><\/p><\/a><\/a>

SINGAPORE & SAN DIEGO--(BUSINESS WIRE)--GemPharmatech, an international provider of in vivo efficacy testing and genetically engineered animal models, and Humlab Global, a Singapore-based developer of humanized mouse models and translational research solutions, today announced the signing of an agreement for the global distribution of existing and novel humanized strains.<\/p>

\nThe rapid development of advanced therapeutics has increased the need for in vivo models that better predict drug efficacy and clinical translation. Humanized strains allow researchers to observe the efficacy of therapies in a context that more closely mirrors human physiology.<\/p>

\n\u201cHumlab\u2019s models are a special addition to our humanized model library,\u201d said Dr. Xiang Gao, Founder and Chairman of GemPharmatech. \u201cTheir mission to shift the focus from \u2018expanding lifespan\u2019 to \u2018expanding healthspan\u2019 is one we deeply admire.\u201d<\/p>

\nHumlab\u2019s unique humanized aging models offer mechanism\u2011level testing of interventions that address senescence, tissue degeneration, and other hallmarks of aging. The agreement also includes models that deliver insights across a range of therapeutic areas, including:<\/p>

\n- Autoimmune and inflammatory disease (IBD, SLE)\n- Metabolic disease (MASH)\n- Oncology\n- Infectious disease<\/p>

\nAmong these, Humlab's novel humanized liver mouse model offers researchers a new platform for studying liver-specific immune and metabolic disease mechanisms, a capability expected to be central to the collaboration.<\/p>

\nDr. Qingfeng Chen, Founder and Director of Humlab, said the agreement represents a win-win for both companies. \u201cThe expertise that both our respective companies bring to model development and distribution will enhance our reach and provide a more competitive solution for drug developers across the world.\u201d<\/p>

\n\u201cOur goal as a company has always been to have the tools ready for scientists when they need them,\u201d said Dr. Brandy Wilkinson, North American CEO of GemPharmatech. \u201cThis agreement will be empowering to researchers across numerous indications where these models can make the biggest difference for patients.\u201d<\/p>

\nChen concluded, \"We are confident this partnership will make a meaningful contribution to the global biopharmaceutical ecosystem.\"<\/p>

\nAbout GemPharmatech<\/b><\/p>

\nGemPharmatech is a leading global contract research organization offering end-to-end integrated preclinical services, built on the world's largest library of genetically engineered mouse models and advanced in vivo platforms. With more than 30,000 strains of knockout, conditional knockout, humanized and immunodeficient mice, GemPharmatech enables researchers worldwide to accelerate therapeutic innovation across oncology, immunology, neurodegenerative diseases and beyond. The company also provides custom model generation and microbiome research services, along with custom breeding, vivarium rental services. To learn more, visit: www.gempharmatech.com<\/a>.<\/p>

\nAbout Humlab Global Pte. Ltd.<\/b><\/p>

\nHumlab Global specializes in humanized mouse model development, immune reconstitution technologies, PDX\/PDO biobanking, and preclinical translational research, and leverages the premier scientific resources in Singapore. Its models are recognized as being among the world's best in terms of reconstitution efficiency, stability, and clinical relevance. Humlab has proven capabilities in serving international pharmaceutical companies and top-tier research teams. To learn more visit: www.humlab-global.com<\/a>.<\/p> Contacts<\/b>

\nMedia Contact<\/b>John Jackson\nGemPharmatech\njohn.jackson@gempharmatech.com<\/a>858-220-8790<\/p>","protected":false},"excerpt":{"rendered":"

Global distribution deal brings Humlab’s humanized models spanning aging, autoimmune and metabolic disease, oncology, and infectious disease to GemPharmatech’s already robust strain library and international research network.SINGAPORE & SAN DIEGO–(BU…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-36835","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36835"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36835\/revisions"}],"predecessor-version":[{"id":36836,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/36835\/revisions\/36836"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}